M. Cremona

发表

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

B. Hennessy, J. Crown, S. Furney, 2018, PloS one.

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

B. Hennessy, A. O'Grady, S. Toomey, 2014, Breast Cancer Research and Treatment.

Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer

L. Trusolino, A. Bertotti, B. Hennessy, 2020, International journal of cancer.

Elevated levels of the acute‐phase serum amyloid are associated with heightened lung cancer risk

C. la Vecchia, U. Pastorino, C. Verri, 2010, Cancer.

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

L. Liotta, V. Espina, B. Hennessy, 2017, Oncotarget.

AMPK-regulated miRNA-2103 p is activated during ischaemic neuronal injury and modulates PI 3 Kp 70 S 6 K signalling

Stefan J. Haunsberger, N. Plesnila, B. Hennessy, 2021 .

Bsx, an evolutionary conserved Brain Specific homeoboX gene expressed in the septum, epiphysis, mammillary bodies and arcuate nucleus.

V. Broccoli, G. Cossu, E. Colombo, 2004, Gene expression patterns : GEP.

Preclinical Drug Testing of the CDK 4/6 Inhibitor Palbociclib in Combination With a PI3K or MEK Inhibitor in Colorectal Cancer Cell Lines

B. Hennessy, A. Farrelly, S. Madden, 2021 .

A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin

W. Kolch, B. Hennessy, J. Crown, 2022, Journal of personalized medicine.

BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors

D. Huntsman, M. Carey, J. McAlpine, 2022, British Journal of Cancer.

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer

B. Hennessy, J. Crown, J. Meiller, 2020, Therapeutic advances in medical oncology.

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation

G. Mills, M. Carey, B. Hennessy, 2013, Molecular oncology.

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

P. Morris, B. Hennessy, A. Farrelly, 2021, Journal of Translational Medicine.

A preclinical evaluation of the PI 3 K alpha / delta dominant 3 inhibitor BAY 80-6946 in HER 2-positive breast cancer models 4 with acquired resistance to the HER 2-targeted therapies 5 trastuzumab and lapatinib 6

B. Hennessy, A. O'Grady, S. Toomey, 2015 .

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers

A. Hopkins, B. Hennessy, S. Vellanki, 2018, Therapeutic advances in medical oncology.

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

G. Cavalleri, B. Hennessy, J. Crown, 2016, Oncotarget.

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

C. Collins, S. Volik, Shawn Anderson, 2019, Cancer Cell International.

Stratification of clear cell renal cell carcinoma by signaling pathway analysis

E. Petricoin, L. Liotta, V. Espina, 2014, Expert review of proteomics.

BCL-2 system analysis identifies high-risk colorectal cancer patients

Manuel Salto-Tellez, Pierre Laurent-Puig, Jochen H M Prehn, 2016, Gut.

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer

Mark Lawler, Manuel Salto-Tellez, Pierre Laurent-Puig, 2016, Clinical Cancer Research.

Chapter 9 – Clinical Proteomics and Molecular Pathology

E. Petricoin, L. Liotta, V. Espina, 2009 .

Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate

M. Gehrmann, J. Prehn, H. Verheul, 2019, Proteomics. Clinical applications.

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

G. Mills, B. Hennessy, Lydia W. T. Cheung, 2018, BMC Cancer.

Proteomics study of medullary thyroid carcinomas expressing RET germ‐line mutations: Identification of new signaling elements

M. Pierotti, C. Lanzi, G. Cassinelli, 2009, Molecular carcinogenesis.

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer

P. Morris, A. Hill, B. Hennessy, 2018, Therapeutic advances in medical oncology.

In silico prediction and experimental validation of natural antisense transcripts in two cancer-associated regions of human chromosome 6.

L. Monti, F. Acquati, R. Taramelli, 2009, International journal of oncology.

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

P. Morris, K. O'Byrne, B. Hennessy, 2020, Journal of Translational Medicine.

Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development

A. Farrelly, S. Madden, J. McBryan, 2022, Cancer Gene Therapy.

Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea

J. Burke, K. Sheahan, B. Hennessy, 2019, Journal of Molecular Medicine.

Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.

M. Salto‐Tellez, D. Longley, P. Laurent-Puig, 2016 .

A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence.

M. Salto‐Tellez, P. Johnston, P. Laurent-Puig, 2016 .

AMPK‐regulated miRNA‐210‐3p is activated during ischaemic neuronal injury and modulates PI3K‐p70S6K signalling

Stefan J. Haunsberger, N. Plesnila, B. Hennessy, 2021, Journal of neurochemistry.

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

P. Morris, K. O'Byrne, B. Hennessy, 2020, Journal of Translational Medicine.

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

A. Farrelly, S. Toomey, M. Cremona, 2023, Cancer biology & therapy.

Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression

S. Sukumar, K. Brennan, L. Hudson, 2022, Cancers.

Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea

K. Sheahan, B. Hennessy, J. Prehn, 2019, Journal of Molecular Medicine.

Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A

M. Duffy, B. Hennessy, J. Crown, 2020, Investigational New Drugs.

Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

K. O'Byrne, L. Hudson, B. Hennessy, 2015, International journal of molecular sciences.

Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

K. O'Byrne, L. Hudson, B. Hennessy, 2023, International journal of molecular sciences.

Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing

Wendy K Chung, W. Chung, S. Bale, 2015, Genetics in Medicine.

Comparative analysis of deeply phenotyped GBM cohorts of ‘short-term’ and ‘long-term’ survivors

D. Lambrechts, M. Lamfers, S. Leenstra, 2023, Journal of Neuro-Oncology.